An Update on the Pathophysiology of Atopic Dermatitis

Dermatologic Clinics

Volumn 35, Issue 3, 2017, Pages 317-326

  Malik, Kunal ^a,b,c,e   Heitmiller, Kerry D ^d,e   Czarnowicki, Tali ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c SUNY Downstate Medical Center   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e NONE   (United States)

Author keywords

Atopic dermatitis; Epithelial barrier; Immune dysregulation; Microbiome; Pathophysiology

Indexed keywords

APREMILAST; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CHEMOKINE RECEPTOR ANTAGONIST; CORTICOSTEROID DERIVATIVE; CRISABOROLE; CYTOKINE; DUPILUMAB; FEZAKINUMAB; FILAGGRIN; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 31; KAPPA OPIATE RECEPTOR AGONIST; PATTERN RECOGNITION RECEPTOR; PHOSPHODIESTERASE; PLACEBO; PROTEIN SPINK5; SECUKINUMAB; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SKIN LIPID; T LYMPHOCYTE RECEPTOR; TEZEPELUMAB; THYMIC STROMAL LYMPHOPOIETIN; TIGHT JUNCTION PROTEIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; UNCLASSIFIED DRUG; USTEKINUMAB; VANILLOID RECEPTOR 1 ANTAGONIST;

ADAPTIVE IMMUNITY; ATOPIC DERMATITIS; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DENDRITIC CELL; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; IMMUNE DYSREGULATION; INNATE IMMUNITY; LOSS OF FUNCTION MUTATION; LYMPHOCYTE PROLIFERATION; MICROBIAL DIVERSITY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SKIN FLORA; SKIN PRURITUS; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; TH22 CELL; TH9 CELL; ENVIRONMENTAL EXPOSURE; FUNCTIONS OF THE SKIN AND ITS APPENDAGES; HELPER CELL; IMMUNOLOGY; MICROBIOLOGY; MICROFLORA; SKIN;

ADAPTIVE IMMUNITY; DENDRITIC CELLS; DERMATITIS, ATOPIC; ENVIRONMENTAL EXPOSURE; HUMANS; IMMUNITY, INNATE; MICROBIOTA; SKIN; SKIN PHYSIOLOGICAL PHENOMENA; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 85018411962     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2017.02.006     Document Type: Review

References (78)

1. Leung, D.Y., Clinical implications of new mechanistic insights into atopic dermatitis. Curr Opin Pediatr 28 (2016), 456–462.
2. Paternoster, L., Standl, M., Waage, J., et al. Multi-ethnic genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet, 47, 2015, 1449.
3. D'Auria, E., Banderali, G., Barberi, S., et al. Atopic dermatitis: recent insight on pathogenesis and novel therapeutic target. Asian Pac J Allergy Immunol 34 (2016), 98–108.
4. Tang, T.S., Bieber, T., Williams, H.C., Does “autoreactivity” play a role in atopic dermatitis?. J Allergy Clin Immunol 129 (2012), 1209–1215.e2.
5. Williams, M.R., Gallo, R.L., The role of the skin microbiome in atopic dermatitis. Curr Allergy Asthma Rep, 15, 2015, 65.
6. Wang, D., Beck, L.A., Immunologic targets in atopic dermatitis and emerging therapies: an update. Am J Clin Dermatol 17:5 (2016), 425–443.
7. Mjosberg, J., Eidsmo, L., Update on innate lymphoid cells in atopic and nonatopic inflammation in the airways and skin. Clin Exp Allergy 44 (2014), 1033–1043.
8. Kuo, I.H., Carpenter-Mendini, A., Yoshida, T., et al. Activation of epidermal toll-like receptor 2 enhances tight junction function: implications for atopic dermatitis and skin barrier repair. J Invest Dermatol 133 (2013), 988–998.
9. Gittler, J.K., Shemer, A., Suarez-Farinas, M., et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 130 (2012), 1344–1354.
10. Czarnowicki, T., Gonzalez, J., Shemer, A., et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J Allergy Clin Immunol 136 (2015), 104–115.e7.
11. Shroff, A., Guttman-Yassky, E., Successful use of ustekinumab therapy in refractory severe atopic dermatitis. JAAD Case Rep 1 (2015), 25–26.
12. Samorano, L.P., Hanifin, J.M., Simpson, E.L., et al. Inadequate response to ustekinumab in atopic dermatitis - a report of two patients. J Eur Acad Dermatol Venereol 30 (2016), 522–523.
13. Khattri, S., Brunner, P.M., Garcet, S., et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol 26:1 (2016), 28–35.
14. Weiss, D., Schaschinger, M., Ristl, R., et al. Ustekinumab treatment in severe atopic dermatitis: down-regulation of T-helper 2/22 expression. J Am Acad Dermatol 76:1 (2016), 91–97.e3.
15. Guttman-Yassky, E., Nograles, K.E., Krueger, J.G., Contrasting pathogenesis of atopic dermatitis and psoriasis–part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol 127 (2011), 1420–1432.
16. Guttman-Yassky, E., Nograles, K.E., Krueger, J.G., Contrasting pathogenesis of atopic dermatitis and psoriasis–part I: clinical and pathologic concepts. J Allergy Clin Immunol 127 (2011), 1110–1118.
17. Saluja, R., Khan, M., Church, M.K., et al. The role of IL-33 and mast cells in allergy and inflammation. Clin Transl Allergy, 5, 2015, 33.
18. Balato, A., Lembo, S., Mattii, M., et al. IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation. Exp Dermatol 21 (2012), 892–894.
19. Wang, A.X., Xu Landen, N., New insights into T cells and their signature cytokines in atopic dermatitis. IUBMB Life 67 (2015), 601–610.
20. Clark, R.A., Schlapbach, C., TH9 cells in skin disorders. Semin Immunopathol 39:1 (2016), 47–54.
21. Berker, M., Frank, L.J., Gessner, A.L., et al. Allergies - A T cells perspective in the era beyond the TH1/TH2 paradigm. Clin Immunol 174 (2016), 73–83.
22. Esaki, H., Brunner, P.M., Renert-Yuval, Y., et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol 138:6 (2016), 1639–1651.
23. Ciprandi, G., De Amici, M., Giunta, V., et al. Serum interleukin-9 levels are associated with clinical severity in children with atopic dermatitis. Pediatr Dermatol 30 (2013), 222–225.
24. Ma, L., Xue, H.B., Guan, X.H., et al. Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis. Clin Exp Immunol 175 (2014), 25–31.
25. Nograles, K.E., Zaba, L.C., Guttman-Yassky, E., et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159 (2008), 1092–1102.
26. Clausen, M.L., Jungersted, J.M., Andersen, P.S., et al. Human beta-defensin-2 as a marker for disease severity and skin barrier properties in atopic dermatitis. Br J Dermatol 169 (2013), 587–593.
27. Howell, M.D., Fairchild, H.R., Kim, B.E., et al. Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Invest Dermatol 128 (2008), 2248–2258.
28. Kabashima-Kubo, R., Nakamura, M., Sakabe, J., et al. A group of atopic dermatitis without IgE elevation or barrier impairment shows a high Th1 frequency: possible immunological state of the intrinsic type. J Dermatol Sci 67 (2012), 37–43.
29. Gutowska-Owsiak, D., Schaupp, A.L., Salimi, M., et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol 21 (2012), 104–110.
30. Novak, N., Koch, S., Allam, J.P., et al. Dendritic cells: bridging innate and adaptive immunity in atopic dermatitis. J Allergy Clin Immunol 125 (2010), 50–59.
31. Moosbrugger-Martinz, V., Tripp, C.H., Clausen, B.E., et al. Atopic dermatitis induces the expansion of thymus-derived regulatory T cells exhibiting a Th2-like phenotype in mice. J Cell Mol Med 20 (2016), 930–938.
32. Saporito, R.C., Cohen, D.J., Apremilast use for moderate-to-severe atopic dermatitis in pediatric patients. Case Rep Dermatol 8 (2016), 179–184.
33. Noda, S., Suarez-Farinas, M., Ungar, B., et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol 136 (2015), 1254–1264.
34. Suarez-Farinas, M., Dhingra, N., Gittler, J., et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol 132 (2013), 361–370.
35. Czarnowicki, T., Esaki, H., Gonzalez, J., et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. J Allergy Clin Immunol 136 (2015), 941–951.e3.
36. Yu, H.S., Kang, M.J., Kwon, J.W., et al. Claudin-1 polymorphism modifies the effect of mold exposure on the development of atopic dermatitis and production of IgE. J Allergy Clin Immunol 135 (2015), 827–830.e5.
37. Lee, H.J., Lee, S.H., Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol Res 6 (2014), 276–287.
38. Palmer, C.N., Irvine, A.D., Terron-Kwiatkowski, A., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38 (2006), 441–446.
39. Szegedi, A., Filaggrin mutations in early- and late-onset atopic dermatitis. Br J Dermatol 172 (2015), 320–321.
40. Riethmuller, C., McAleer, M.A., Koppes, S.A., et al. Filaggrin breakdown products determine corneocyte conformation in patients with atopic dermatitis. J Allergy Clin Immunol 136 (2015), 1573–1580.e1-2.
41. Jungersted, J.M., Scheer, H., Mempel, M., et al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy 65 (2010), 911–918.
42. Cole, C., Kroboth, K., Schurch, N.J., et al. Filaggrin-stratified transcriptomic analysis of pediatric skin identifies mechanistic pathways in patients with atopic dermatitis. J Allergy Clin Immunol 134 (2014), 82–91.
43. Ewald, D.A., Malajian, D., Krueger, J.G., et al. Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways. BMC Med Genomics, 8, 2015, 60.
44. Sajic, D., Asiniwasis, R., Skotnicki-Grant, S., A look at epidermal barrier function in atopic dermatitis: physiologic lipid replacement and the role of ceramides. Skin Therapy Lett 17 (2012), 6–9.
45. Vieira, B.L., Lim, N.R., Lohman, M.E., et al. Complementary and alternative medicine for atopic dermatitis: an evidence-based review. Am J Clin Dermatol 17:6 (2016), 557–581.
46. De Benedetto, A., Rafaels, N.M., McGirt, L.Y., et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 127 (2011), 773–786.e1-7.
47. Yuki, T., Komiya, A., Kusaka, A., et al. Impaired tight junctions obstruct stratum corneum formation by altering polar lipid and profilaggrin processing. J Dermatol Sci 69 (2013), 148–158.
48. Ali, S.M., Yosipovitch, G., Skin pH: from basic science to basic skin care. Acta Derm Venereol 93 (2013), 261–267.
49. Eberlein-Konig, B., Schafer, T., Huss-Marp, J., et al. Skin surface pH, stratum corneum hydration, trans-epidermal water loss and skin roughness related to atopic eczema and skin dryness in a population of primary school children. Acta Derm Venereol 80 (2000), 188–191.
50. Jang, H., Matsuda, A., Jung, K., et al. Skin pH is the master switch of kallikrein 5-mediated skin barrier destruction in a murine atopic dermatitis model. J Invest Dermatol 136 (2016), 127–135.
51. Lee, S.E., Jeong, S.K., Lee, S.H., Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis. Yonsei Med J 51 (2010), 808–822.
52. Horimukai, K., Morita, K., Narita, M., et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol 134 (2014), 824–830.e6.
53. Czarnowicki, T., Krueger, J.G., Guttman-Yassky, E., Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. J Allergy Clin Immunol Pract 2 (2014), 371–379 [quiz: 380–1].
54. Tauber, M., Balica, S., Hsu, C.Y., et al. Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis. J Allergy Clin Immunol 137 (2016), 1272–1274.e1-3.
55. Kong, H.H., Oh, J., Deming, C., et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 22 (2012), 850–859.
56. Nakatsuji, T., Chen, T.H., Two, A.M., et al. Staphylococcus aureus exploits epidermal barrier defects in atopic dermatitis to trigger cytokine expression. J Invest Dermatol 136:11 (2016), 2192–2200.
57. Brauweiler, A.M., Goleva, E., Leung, D.Y., Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). J Invest Dermatol 134 (2014), 2114–2121.
58. Ong, P.Y., Recurrent MRSA skin infections in atopic dermatitis. J Allergy Clin Immunol Pract 2 (2014), 396–399.
59. Nograles, K.E., Zaba, L.C., Shemer, A., et al. IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 123 (2009), 1244–1252.e2.
60. Wolk, K., Mitsui, H., Witte, K., et al. Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function. Clin Cancer Res 20 (2014), 5507–5516.
61. van der Does, A.M., Kenne, E., Koppelaar, E., et al. Vitamin D(3) and phenylbutyrate promote development of a human dendritic cell subset displaying enhanced antimicrobial properties. J Leukoc Biol 95 (2014), 883–891.
62. Seite, S., Flores, G.E., Henley, J.B., et al. Microbiome of affected and unaffected skin of patients with atopic dermatitis before and after emollient treatment. J Drugs Dermatol 13 (2014), 1365–1372.
63. Panduru, M., Panduru, N.M., Salavastru, C.M., et al. Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies. J Eur Acad Dermatol Venereol 29 (2015), 232–242.
64. Bath-Hextall, F.J., Birnie, A.J., Ravenscroft, J.C., et al. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol 163 (2010), 12–26.
65. Werfel, T., Heratizadeh, A., Niebuhr, M., et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol 136 (2015), 96–103.e9.
66. Jang, M., Kim, H., Kim, Y., et al. The crucial role of IL-22 and its receptor in thymus and activation regulated chemokine production and T-cell migration by house dust mite extract. Exp Dermatol 25 (2016), 598–603.
67. Al-Ghouleh, A., Johal, R., Sharquie, I.K., et al. The glycosylation pattern of common allergens: the recognition and uptake of Der p 1 by epithelial and dendritic cells is carbohydrate dependent. PLoS One, 7, 2012, e33929.
68. Kouzaki, H., O'Grady, S.M., Lawrence, C.B., et al. Proteases induce production of thymic stromal lymphopoietin by airway epithelial cells through protease-activated receptor-2. J Immunol 183 (2009), 1427–1434.
69. Landheer, J., Giovannone, B., Mattson, J.D., et al. Epicutaneous application of house dust mite induces thymic stromal lymphopoietin in nonlesional skin of patients with atopic dermatitis. J Allergy Clin Immunol 132 (2013), 1252–1254.
70. Totri, C.R., Diaz, L., Eichenfield, L.F., 2014 update on atopic dermatitis in children. Curr Opin Pediatr 26 (2014), 466–471.
71. Weidinger, S., Novak, N., Atopic dermatitis. Lancet 387 (2016), 1109–1122.
72. Brown, S.J., Kroboth, K., Sandilands, A., et al. Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect. J Invest Dermatol 132 (2012), 98–104.
73. Saunders, S.P., Goh, C.S., Brown, S.J., et al. Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. J Allergy Clin Immunol 132 (2013), 1121–1129.
74. Oyoshi, M.K., He, R., Kumar, L., et al. Cellular and molecular mechanisms in atopic dermatitis. Adv Immunol 102 (2009), 135–226.
75. Mu, Z., Zhao, Y., Liu, X., et al. Molecular biology of atopic dermatitis. Clin Rev Allergy Immunol 47 (2014), 193–218.
76. Kato, A., Fukai, K., Oiso, N., et al. Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br J Dermatol 148 (2003), 665–669.
77. Silverberg, N.B., A practical overview of pediatric atopic dermatitis, part 1: epidemiology and pathogenesis. Cutis 97 (2016), 267–271.
78. Lyons, J.J., Milner, J.D., Stone, K.D., Atopic dermatitis in children: clinical features, pathophysiology, and treatment. Immunol Allergy Clin North Am 35 (2015), 161–183.